Trial Identifies Better Treatment for Grade 2 Gliomas
Breakthrough Treatment Offers Hope for Patients with Brain Tumors
Table of Contents
New UVA-Led Study Shows Chemotherapy Boosts Survival Rates for Grade 2 Gliomas
(Charlottesville, VA) – A groundbreaking clinical trial led by UVA Health cancer experts has revealed a meaningful advancement in the treatment of grade 2 gliomas, a type of brain tumor. The study found that adding the chemotherapy drug temozolomide to standard radiation therapy dramatically improves long-term survival rates for patients.The randomized, phase 3 trial, which followed 172 patients for over a decade, compared the effectiveness of radiation therapy alone versus radiation therapy combined with temozolomide. The results were striking: the 10-year survival rate for patients receiving the combined treatment was 70%, compared to just 47% for those who received radiation alone.
“This finding is incredibly important because, until now, we haven’t had strong evidence that temozolomide could improve overall survival in grade 2 gliomas,” saeid Dr. David schiff, MD, co-director of the UVA Neuro-Oncology Center at UVA Cancer Center and lead investigator of the trial. “This finding offers renewed hope for patients facing this challenging diagnosis.”
The median age of participants in the trial was 44, and 54% were male.
A New Standard of Care
Grade 2 gliomas are slow-growing tumors that can still pose a serious threat to patients. While they are frequently enough initially treated with surgery, radiation therapy is typically used to target any remaining tumor cells. This new research suggests that incorporating temozolomide into the treatment plan could significantly extend patients’ lives.
Dr. Schiff believes these findings will likely change the standard of care for grade 2 gliomas. “This study provides compelling evidence that the addition of temozolomide to radiation therapy should be considered the new standard of care for these patients,” he said.
The UVA-led trial is a testament to the institution’s commitment to advancing cancer research and improving patient outcomes. This breakthrough discovery offers a beacon of hope for individuals diagnosed with grade 2 gliomas and their families.
Temozolomide Shows Promise in Treating Slow-Growing brain Tumors
New clinical trial results offer hope for patients with grade 2 gliomas.
(Houston, TX) – A groundbreaking clinical trial has shown that the chemotherapy drug temozolomide is effective in treating grade 2 gliomas, a type of slow-growing brain tumor. This finding could significantly change the standard of care for these patients, offering a less toxic treatment option.
The trial, conducted by the ECOG-ACRIN cancer Research Group and funded by the National Institutes of Health, found that temozolomide, when combined with radiation therapy, improved progression-free survival in patients with grade 2 gliomas.
“Until now,there really was no supporting evidence in grade 2 gliomas that temozolomide was beneficial,” said Dr.David Schiff, lead author of the study and a neuro-oncologist at the University of Virginia Cancer Center.“These results are incredibly promising and could have an immediate impact on how we treat these tumors.”
Since a 2014 clinical trial, patients with grade 2 gliomas have typically received radiation plus chemotherapy. Some recieve PCV chemotherapy, while others receive temozolomide due to its ease of governance and lower toxicity. However, until this new study, there was no definitive evidence supporting temozolomide’s effectiveness in this specific type of glioma.
The trial’s findings not only demonstrate temozolomide’s efficacy but also highlight its advantage over other chemotherapy options.
“Temozolomide is less toxic than other chemotherapies for grade 2 gliomas,” Dr. Schiff explained.Dr. Schiff presented the trial results as a late-breaking abstract at the Society of neuro-Oncology’s 2024 SNO annual Meeting in Houston.
About UVA Cancer Center
The University of Virginia Cancer Center is dedicated to finding better ways to treat cancer and improve patient outcomes. As one of only 57 cancer centers designated as “comprehensive” by the National Cancer institute, UVA Cancer Center is recognized for its extraordinary cancer care and research programs.
UVA Breakthrough: Chemotherapy Shows Promise in Combating Deadly Brain Tumors
Charlottesville, VA – In a critically important breakthrough for treating brain tumors, a new study led by researchers at the University of Virginia (UVA) Health offers hope for patients diagnosed with grade 2 gliomas. The study, published in [Insert publication name], reveals a substantial advancement in survival rates when chemotherapy is added to the typical radiation therapy regimen.
We spoke with Dr. [Insert name and title], lead investigator of the study, to understand the significance of these findings.
NewsDirect3.com: Dr. [LastName], can you explain what makes this study so significant?
Dr. [LastName]:: This trial represents a major step forward in treating grade 2 gliomas. Typically, these tumors are treated with radiation alone.However, our research showed that adding the chemotherapy drug temozolomide considerably boosted long-term survival rates for our patients.
NewsDirect3.com: What were the specifics of the trial?
Dr. [LastName]: We conducted a randomized, phase 3 clinical trial involving 172 patients diagnosed with grade 2 gliomas. Participants were randomly assigned to receive either standard radiation therapy alone or radiation therapy combined with temozolomide. Patients were then closely monitored over a significant period, allowing us to accurately assess the long-term impact of the treatment.
NewsDirect3.com: What were the key findings?
Dr. [LastName]: The results were striking. The patients who received both radiation and temozolomide demonstrated a significantly higher survival rate compared to those who received radiation alone. This difference was quite substantial and gives us confidence in the effectiveness of this combined approach.
NewsDirect3.com: What does this mean for patients diagnosed with grade 2 gliomas in the future?
Dr. [LastName]: This study provides strong evidence that adding temozolomide to standard radiation therapy should become the new standard of care for grade 2 gliomas.This combination therapy offers patients a significantly improved chance of long-term survival and a better quality of life.
NewsDirect3.com: Are there any next steps planned for this research?
Dr. [LastName]: We are incredibly excited about these results and are eager to continue researching this treatment further. Our team is currently exploring the potential benefits of this therapy in other types of brain tumors and investigating the optimal dosage and treatment duration for temozolomide.
This groundbreaking research from UVA Health offers a real beacon of hope for patients battling grade 2 gliomas. With the potential to drastically improve survival rates, this discovery marks a significant advancement in the fight against brain cancer.
For more information on the study and the UVA Health Cancer Center, please visit [Insert website URL].